Lubiprostone

Member of a bicyclic fatty acid class of compounds derived from PROSTAGLANDIN E1 involved in chloride channel gating.

Also Known As:

Amitiza; Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)-; RU 0211; RU-0211; RU0211; SPI 0211; SPI-0211; SPI0211; 0211, RU; 0211, SPI; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid

Networked: 224 relevant articles (56 outcomes, 62 trials/studies)

Relationship Network

Drug Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Monounsaturated Fatty Acids: 676
      - Alprostadil: 3107
        Lubiprostone: 224

Experts

1.	Rao, Satish S C: 10 articles (01/2021 - 08/2006)
2.	Ueno, Ryuji: 10 articles (02/2015 - 11/2004)
3.	Chey, William D: 7 articles (01/2020 - 08/2008)
4.	Lichtlen, Peter: 6 articles (01/2022 - 01/2018)
5.	Losch-Beridon, Taryn: 6 articles (01/2022 - 01/2017)
6.	Lacy, Brian E: 6 articles (04/2015 - 07/2006)
7.	Mareya, Shadreck: 5 articles (01/2022 - 01/2018)
8.	Camilleri, Michael: 5 articles (11/2019 - 05/2006)
9.	Ueno, R: 5 articles (03/2012 - 06/2007)
10.	Higurashi, Takuma: 4 articles (07/2021 - 01/2017)

Related Diseases

1.	Constipation 05/22/2023 - "Lubiprostone treatment induces relief from the most bothersome symptoms associated with constipation." 01/01/2006 - "Significantly greater improvements occurred with lubiprostone than placebo in the degree of straining, stool consistency and constipation severity (where reported) in both pivotal studies (p < 0.05 for all comparisons at all timepoints). " 01/01/2006 - "In two pivotal, randomised, double-blind, multicentre phase III studies in patients with chronic idiopathic constipation, the frequency of spontaneous bowel movements (SBMs) was significantly greater in patients receiving lubiprostone 24microg twice daily than in those receiving placebo at each weekly timepoint throughout both 4-week studies (p < 0.05). " 01/01/2019 - "In this review, we were able to conclude that lubiprostone, when used for chronic idiopathic constipation, has a significantly beneficial effect on both patients' symptoms and their QOL. " 11/01/2014 - "Pairwise comparisons showed significantly greater overall improvement for abdominal discomfort (P=0.047), straining (P<0.001), constipation severity (P=0.007), and stool consistency (P<0.001) with lubiprostone compared with placebo. "
2.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/01/2009 - "A multi-center study of patients with IBS-C found that 8 microg of lubiprostone twice-daily improved both global and individual symptoms of irritable bowel syndrome. " 06/01/2011 - "Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study." 02/01/2015 - "Long-term administration of lubiprostone significantly increased scores from the Short-Form health survey and irritable bowel syndrome quality-of-life questionnaire, compared with baseline. " 04/01/2008 - "Lubiprostone significantly improved gastrointestinal symptoms of irritable bowel syndrome with constipation at all doses. " 04/01/2016 - "Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials."
3.	Pain (Aches) 05/01/2015 - "Lubiprostone significantly improved symptoms of OIC and was well tolerated in patients with chronic noncancer pain." 04/01/2008 - "After 2 months, all lubiprostone groups showed significantly greater improvements in mean abdominal discomfort/pain scores (P < or = 0.039). " 04/01/2008 - "After 1 month, lubiprostone showed significantly greater improvements in mean abdominal discomfort/pain scores vs. placebo (P = 0.023). " 11/01/2016 - "Rates of response were higher with lubiprostone vs. placebo for the composite endpoint of improved pain and stool frequency (26.3% vs. 15.3%, respectively; P = 0.008) and the composite endpoint of improved bloating and stool frequency (23.8% vs. 12.6%, respectively; P = 0.012). " 11/01/2016 - "Lubiprostone treatment was well tolerated and improved symptoms and signs of OIC in this 9-month, open-label study of patients with chronic noncancer pain."
4.	Opioid-Induced Constipation 05/01/2020 - "Compared with the placebo groups in idiopathic and opioid-induced constipation, the lubiprostone groups significantly improved in 24-h SBM frequency [relative risk: 1.28, 95% confidence interval, 1.11-1.49, and 1.23, 1.14-1.32] and weekly frequency >3 SBM/week (1.68, 1.41-2.01, and 1.43, 1.01-2.04), respectively. " 05/01/2020 - "It is unclear whether the efficacy of lubiprostone for spontaneous bowel movement (SBM) and the adverse events are similar between idiopathic and opioid-induced constipation and between East-Asian and Western populations. " 05/01/2020 - "We conducted a meta-analysis to compare efficacy and safety of lubiprostone in two populations with idiopathic vs opioid-induced constipation. " 05/01/2020 - "Differences in efficacy and safety of lubiprostone used for idiopathic vs opioid-induced constipation: meta-analysis of East Asian and Western populations." 05/01/2015 - "Adults with opioid-induced constipation (OIC; <3 spontaneous bowel movements [SBMs] per week) were randomized 1:1 to double-blind lubiprostone 24 μg or placebo twice daily for 12 weeks. "
5.	Abdominal Pain (Pain, Abdominal) 11/01/2016 - "Lubiprostone was significantly more effective than placebo in improving abdominal pain or bloating, and also in composite endpoints that included stool frequency." 10/01/2011 - "In clinical trials, lubiprostone reduced the severity of abdominal pain. " 10/01/2020 - "In terms of abdominal pain, lubiprostone provided significantly better symptoms relief, particularly after 1 month of treatment. " 10/01/2020 - "Lubiprostone RCTs reporting outcomes of spontaneous bowel movements (SBM) and abdominal pain or discomfort were deemed eligible. " 11/01/2016 - "Response rates were also higher with lubiprostone vs. placebo for abdominal pain alone (P = 0.005) and bloating alone (P = 0.012). "

Related Drugs and Biologics

1.	Chloride Channels (Chloride Channel)
2.	linaclotide
3.	prucalopride
4.	tegaserod (Zelnorm)
5.	Polyethylene Glycols (Polyethylene Glycol)
6.	Opioid Analgesics (Opioids)
7.	Secretagogues
8.	Lactulose (Duphalac)
9.	naloxegol
10.	plecanatide

Related Therapies and Procedures

1.	Therapeutics
2.	Acupuncture Points (Acupuncture Point)
3.	Enema (Enemas)
4.	Drug Tapering
5.	Stents